The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?

First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.

(2017) J. Delord et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

(2017) J. R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy

(2010) Biswa M. Padhy et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Perifosine-Related Rapidly Progressive Corneal Ring Infiltrate

(2010) Jeremy D Keenan et al.   CORNEA

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab-induced hypertrichosis of the scalp and eyelashes

(2010) Sergio Vano-Galvan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Persistent Corneal Epithelial Defect Associated With Erlotinib Treatment

(2009) Keegan S Johnson et al.   CORNEA

Ocular Side Effects Associated with Imatinib Mesylate and Perifosine for Gastrointestinal Stromal Tumor

(2009) S. Serdar Dogan et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Reversible posterior leucoencephalopathy syndrome associated with sunitinib

(2009)   INTERNAL MEDICINE JOURNAL

OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB

(2009) J. H. Sherman et al.   NEUROLOGY

The Inhibitory Effects of Trastuzumab on Corneal Neovascularization

(2008) Mete Güler et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Trichomegaly of the eyelashes following treatment with cetuximab

(2008) M. Vaccaro et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway

(2008) J. S. Sebolt-Leopold   CLINICAL CANCER RESEARCH

Persisting Corneal Erosion Under Cetuximab (Erbitux) Treatment (Epidermal Growth Factor Receptor Antibody)

(2008) Claudia G Foerster et al.   CORNEA

Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits

(2008) A S Kitzmann et al.   EYE

Optic disc edema as a possible complication of Imatinib mesylate (Gleevec)

(2008) Soon-Il Kwon et al.   JAPANESE JOURNAL OF OPHTHALMOLOGY

Ulcerative Keratitis in Gastrointestinal Stromal Tumor Patients Treated with Perifosine

(2008) Debraj Shome et al.   OPHTHALMOLOGY